D
David E. Gilham
Researcher at University of Manchester
Publications - 94
Citations - 4117
David E. Gilham is an academic researcher from University of Manchester. The author has contributed to research in topics: Chimeric antigen receptor & T cell. The author has an hindex of 35, co-authored 91 publications receiving 3513 citations. Previous affiliations of David E. Gilham include University of Leicester & University of Dundee.
Papers
More filters
Journal ArticleDOI
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.
Ryan D. Guest,Robert E. Hawkins,Natalia Kirillova,Eleanor J. Cheadle,Jennifer Arnold,Allison F. O'Neill,Joely J Irlam,Kerry A. Chester,John T Kemshead,David M Shaw,M. J. Embleton,Peter L. Stern,David E. Gilham +12 more
TL;DR: Results show that a spacer is not necessary for optimal activity of CIRs but that the optimal design varies, and interestingly, mapping of the scFV epitopes has revealed that the anti-CEA scFv binds close to the amino-terminal of CEA, which is easily accessible to the CIR.
Journal ArticleDOI
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Fiona C Thistlethwaite,Fiona C Thistlethwaite,David E. Gilham,Ryan D. Guest,Dominic G. Rothwell,Manon Pillai,Manon Pillai,Deborah J. Burt,Andrea J. Byatte,Natalia Kirillova,Juan W. Valle,Juan W. Valle,Surinder K. Sharma,Kerry A. Chester,Nigel B. Westwood,Sarah E. R. Halford,Stephen Nabarro,Susan Wan,Eric Austin,Robert E. Hawkins,Robert E. Hawkins +20 more
TL;DR: Improved CAR designs and T cell production methods could improve the systemic persistence and activity, methods to control CAR T ‘on-target, off-tissue’ toxicity are required to enable a clinical impact of this approach in solid malignancies.
Journal ArticleDOI
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.
John S. Bridgeman,Robert E. Hawkins,Steven Bagley,Morgan Blaylock,Mark Holland,David E. Gilham +5 more
TL;DR: Results indicate that CARs containing the CD3ζ transmembrane domain can form a complex with the endogenous TCR that may be beneficial for optimal T cell activation.
Journal ArticleDOI
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H.C. Baumeister,Joana M. Murad,Lillian Werner,Heather Daley,Helene Trebeden-Negre,Joanina K. Gicobi,Adam Schmucker,Jake Reder,Charles L Sentman,David E. Gilham,Frederic Lehmann,Ilene Galinsky,Heidi Dipietro,Kristen Cummings,Nikhil C. Munshi,Richard Stone,Donna Neuberg,Robert J. Soiffer,Glenn Dranoff,Jerome Ritz,Sarah Nikiforow +20 more
TL;DR: Manufactured NKG2D-CAR T cells exhibited functional activity against autologous tumor cells in vitro, but modifications to enhance CAR T-cell expansion and target density may be needed to boost clinical activity.
Journal ArticleDOI
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
TL;DR: The current clinical application of CAR-T cells is reviewed and parameters considered critical for CAR engineering, classified as the three T's ofCAR-T cell manipulation are related.